Interferon-induced sarcoidosis

BMJ Case Reports

Volumn , Issue , 2011, Pages

  Cardoso, Cláudia Sofia ^a   Freire, Ricardo ^a   Alves, Ana ^a   Oliveira, Ana ^a  

^a Centro Hospitalar de Setubal   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DIPEPTIDYL CARBOXYPEPTIDASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACK; BIOPSY; CASE REPORT; CLINICAL FEATURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ERYTHEMA NODOSUM; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; PRIORITY JOURNAL; SARCOIDOSIS; SKIN PIGMENTATION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 79955595817     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.03.2011.3929     Document Type: Article

References (16)

1. Leclerc S, Myers RP, Moussalli J, et al. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med 2003;14:237-43. (Pubitemid 36952702)
2. Fantini F, Padalino C, Gualdi G, et al. Cutaneous lesions as initial signs of interferon alpha-induced sarcoidosis: report of three new cases and review of the literature. Dermatol Ther 2009;22(Suppl 1):S1-7.
3. World Health Organization. Global distribution of hepatitis A, B and C, 2001. Wkly Epidemiol Rec 2002;77:6.
4. Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet 2003;362:2095-100. (Pubitemid 38035201)
5. Abdi EA, Nguyen GK, Ludwig RN, et al. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987;59:896-900. (Pubitemid 17024641)
6. Braverman IM. Sarcoidosis. In: Feedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. Sixth edition. New York, NY: McGraw-Hill 2003:1777-83.
7. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985;75:1488-95. (Pubitemid 15041440)
8. Bäumer I, Zissel G, Schlaak M, et al. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997;16:171-7. (Pubitemid 127498238)
9. Ramos-Casals M, Mañá J, Nardi N, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005;84:69-80. (Pubitemid 40418635)
10. Baughman RP, Sharma OP, Lynch JP 3rd. Sarcoidosis: is therapy effective? Semin Respir Infect 1998;13:255-73.
11. Mert A, Bilir M, Ozaras R, et al. The prevalence of serum antibodies to hepatitis C virus is not increased in patients with sarcoidosis. Respiration 2000;67:592.
12. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
13. Cogrel O, Doutre MS, Marlière V, et al. Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. Br J Dermatol 2002;146:320-4. (Pubitemid 34264409)
14. Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med 2003;97:978-82. (Pubitemid 36944130)
15. Sanders S, Busam K, Tahan SR, et al. Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. J Am Acad Dermatol 2002;46:611-16.
16. Alazemi S, Campos MA. Interferon-induced sarcoidosis. Int J Clin Pract 2006;60:201-11. (Pubitemid 43740500)